⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
KALV News
KalVista Pharmaceuticals, Inc. Common Stock
KLKB1 Inhibitors Market to Reach New Heights by 2034 Owing to the Launch of Novel Therapies | DelveInsight
prnewswire.com
NTLA
ASTX
RZLT
IONS
KALV
BCRX
TAK
KAVL
KalVista Pharmaceuticals Provides Operational Update and Reports Third Quarter Financial Results
businesswire.com
KALV
KalVista Pharmaceuticals Presents New Data Highlighting Patient Satisfaction with EKTERLY ® (sebetralstat) and its Potential in Children Ages 2-11 at the ACAAI 2025 Annual Scientific Meeting
businesswire.com
KALV
KalVista Pharmaceuticals to Present at Upcoming Investor Conferences
businesswire.com
KALV
KalVista Pharmaceuticals to Host Third Quarter Financial Results Conference Call and Webcast on November 11, 2025
businesswire.com
KALV
KalVista Pharmaceuticals to Present New EKTERLY ® (sebetralstat) Data at the American College of Allergy, Asthma & Immunology 2025 Annual Scientific Meeting
businesswire.com
KALV
KalVista Pharmaceuticals Appoints Bilal Arif as Chief Operating Officer and Linea Aspesi as Chief People Officer
businesswire.com
KALV
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
businesswire.com
KALV
KalVista Pharmaceuticals Announces Appointment of Bethany L. Sensenig to Board of Directors
businesswire.com
KALV
KalVista Pharmaceuticals to Present New EKTERLY ® (sebetralstat) Data at the 20 th German Allergy Congress
businesswire.com
KALV